SCHEMBL3205934

SCHEMBL3205934

O=c1cc(Oc2cccnc2)c2ccccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44
PARP1 P09874 3/20 0.42
HTT P42858 2/20 0.42
MAPK1 P28482 1/20 0.42
CYP19A1 P11511 1/20 0.41
ACHE P22303 1/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
IKBKB O14920 1/20 0.41
AURKA O14965 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3202341 0.87 HPGD (0.47) LMNATDP1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13429115 0.86 HPGD (0.51) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2008835 0.84 HPGD (0.54) LMNAALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL3214639 0.80 SMN1; SMN2 (0.49) LMNAALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL13429189 0.80 HPGD (0.47) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL13429178 0.80 HPGD (0.44) LMNAALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL13429184 0.79 GRIN2D (0.45) ALDH1A1SMN1; SMN2KDM4EHPGDCYP1A2
SCHEMBL3216704 0.79 KDM4C (0.53) KDM4EHSD17B10KDM4CIDO1
SCHEMBL13429334 0.79 KDM4E (0.48) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL3220447 0.79 PTK6 (0.41) ALDH1A1SMN1; SMN2KDM4EHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US claimed
WO-2010030967-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH LLC (US) 2010-03-18 WO disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA LMNA 4098/4885TDP1 3728/4885ALDH1A1 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.